Drug Metabolism and Pharmacokinetics, the Blood-brain Barrier, and Central Nervous System Drug Discovery

Overview

Journal NeuroRx

Specialty Neurology

Date 2006 Feb 21

PMID 16489365

Citations 131

Authors

Mohammad S Alavijeh

Mansoor Chishty

M Zeeshan Qaiser

Alan M Palmer

Affiliations

Soon will be listed here.

Abstract

The worldwide market for therapies for CNS disorders is worth more than 50 billion dollars and is set to grow substantially in the years ahead. This is because: 1) the incidence of many CNS disorders (e.g., Alzheimer's disease, stroke, and Parkinson's disease) increase exponentially after age 65 and 2) the number of people in the world over 65 is about to increase sharply because of a marked rise in fertility after World War II. However, CNS research and development are associated with significant challenges: it takes longer to get a CNS drug to market (12-16 years) compared with a non-CNS drug (10-12 years) and there is a higher attrition rate for CNS drug candidates than for non-CNS drug candidates. This is attributable to a variety of factors, including the complexity of the brain, the liability of CNS drugs to cause CNS side effects, and the requirement of CNS drugs to cross the blood-brain barrier (BBB). This review focuses on BBB penetration, along with pharmacokinetics and drug metabolism, in the process of the discovery and development of safe and effective medicines for CNS disorders.

Citing Articles

Investigating blood-brain barrier penetration and neurotoxicity of natural products for central nervous system drug development.

Kato R, Zhang L, Kinatukara N, Huang R, Asthana A, Weber C Sci Rep. 2025; 15(1):7431.

PMID: 40032960 PMC: 11876671. DOI: 10.1038/s41598-025-90888-2.

Molecular screening and dynamics simulation reveal potential phytocompounds in Swertia chirayita targeting the UspA1 protein of Moraxella catarrhalis for COPD therapy.

Uddin M, Chowdhury M, Hossain M, Ahsan A, Hossain M, Barik A PLoS One. 2025; 20(2):e0316275.

PMID: 40019889 PMC: 11870343. DOI: 10.1371/journal.pone.0316275.

Determination of Intrinsic Clearance and Fraction Unbound in Human Liver Microsomes and In Vitro-In Vivo Extrapolation of Human Hepatic Clearance for Marketed Central Nervous System Drugs.

Palacharla V, Nirogi R, Kumar N, Nandakumar K Eur J Drug Metab Pharmacokinet. 2024; 50(2):119-135.

PMID: 39724218 DOI: 10.1007/s13318-024-00931-2.

Potential role of the antimicrobial peptide Tachyplesin III in regulating nontypeable Haemophilus influenzae-induced inflammation in airway epithelial cells.

Jantaruk P, Roytrakul S, Sistayanarain A, Kunthalert D Arch Microbiol. 2024; 206(12):471.

PMID: 39560721 DOI: 10.1007/s00203-024-04196-w.

Therapeutic targeting of senescent cells in the CNS.

Riessland M, Ximerakis M, Jarjour A, Zhang B, Orr M Nat Rev Drug Discov. 2024; 23(11):817-837.

PMID: 39349637 DOI: 10.1038/s41573-024-01033-z.

References

Abbott N . Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005; 25(1):5-23. PMC: 11529509. DOI: 10.1007/s10571-004-1374-y. View

Ohno K, Pettigrew K, Rapoport S . Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol. 1978; 235(3):H299-307. DOI: 10.1152/ajpheart.1978.235.3.H299. View

Shinotoh H, Calne D . The use of PET in Parkinson's disease. Brain Cogn. 1995; 28(3):297-310. DOI: 10.1006/brcg.1995.1259. View

Wilkinson G . Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21):2211-21. DOI: 10.1056/NEJMra032424. View

Gombar V, Polli J, Humphreys J, Wring S, Serabjit-Singh C . Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. J Pharm Sci. 2004; 93(4):957-68. DOI: 10.1002/jps.20035. View

Palmer A . Pharmacotherapy for Alzheimer's disease: progress and prospects. Trends Pharmacol Sci. 2002; 23(9):426-33. DOI: 10.1016/s0165-6147(02)02056-4. View

Clark D . In silico prediction of blood-brain barrier permeation. Drug Discov Today. 2003; 8(20):927-33. DOI: 10.1016/s1359-6446(03)02827-7. View

Subramanian G, Kitchen D . Computational models to predict blood-brain barrier permeation and CNS activity. J Comput Aided Mol Des. 2004; 17(10):643-64. DOI: 10.1023/b:jcam.0000017372.32162.37. View

Green A, Ashwood T . Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. Curr Drug Targets CNS Neurol Disord. 2005; 4(2):109-18. DOI: 10.2174/1568007053544156. View

10.

Wang Q, Rager J, Weinstein K, Kardos P, Dobson G, Li J . Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm. 2004; 288(2):349-59. DOI: 10.1016/j.ijpharm.2004.10.007. View

11.

Goodwin J, Clark D . In silico predictions of blood-brain barrier penetration: considerations to "keep in mind". J Pharmacol Exp Ther. 2005; 315(2):477-83. DOI: 10.1124/jpet.104.075705. View

12.

Kornhuber J, Weigmann H, Rohrich J, Wiltfang J, Bleich S, Meineke I . Region specific distribution of levomepromazine in the human brain. J Neural Transm (Vienna). 2005; 113(3):387-97. DOI: 10.1007/s00702-005-0331-3. View

13.

Lin J, Sahakian D, de Morais S, Xu J, Polzer R, Winter S . The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem. 2003; 3(10):1125-54. DOI: 10.2174/1568026033452096. View

14.

Fu X, Song Z, Fu C, Liang W . A simple predictive model for blood-brain barrier penetration. Pharmazie. 2005; 60(5):354-8. View

15.

Avdeef A . Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem. 2002; 1(4):277-351. DOI: 10.2174/1568026013395100. View

16.

Tang H, Mayersohn M . A novel model for prediction of human drug clearance by allometric scaling. Drug Metab Dispos. 2005; 33(9):1297-303. DOI: 10.1124/dmd.105.004143. View

17.

Kassel D . Applications of high-throughput ADME in drug discovery. Curr Opin Chem Biol. 2004; 8(3):339-45. DOI: 10.1016/j.cbpa.2004.04.015. View

18.

Bergstrom C . In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin Pharmacol Toxicol. 2005; 96(3):156-61. DOI: 10.1111/j.1742-7843.2005.pto960303.x. View

19.

Patsalos P, Abed W, Alavijeh M, OConnell M . The use of microdialysis for the study of drug kinetics: some methodological considerations illustrated with antipyrine in rat frontal cortex. Br J Pharmacol. 1995; 115(3):503-9. PMC: 1908406. DOI: 10.1111/j.1476-5381.1995.tb16362.x. View

20.

Prentis R, Lis Y, Walker S . Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol. 1988; 25(3):387-96. PMC: 1386364. DOI: 10.1111/j.1365-2125.1988.tb03318.x. View